Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

Miguel A. Rubio; Jose A. Cabranes; Andrew V. Schally; Aniceto L. Charro

doi:10.1210/jcem-69-2-444

Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

Miguel A. Rubio, Jose A. Cabranes, Andrew V. Schally, Aniceto L. Charro

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp⁶-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

Original language	English (US)
Pages (from-to)	444-447
Number of pages	4
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	69
Issue number	2
DOIs	https://doi.org/10.1210/jcem-69-2-444
State	Published - Aug 1989
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1210/jcem-69-2-444

Fingerprint Dive into the research topics of 'Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients'. Together they form a unique fingerprint.

Cite this

@article{2563164b05ba40f599cd39f469039129,

title = "Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients",

abstract = "We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.",

author = "Rubio, {Miguel A.} and Cabranes, {Jose A.} and Schally, {Andrew V.} and Charro, {Aniceto L.}",

year = "1989",

month = aug,

doi = "10.1210/jcem-69-2-444",

language = "English (US)",

volume = "69",

pages = "444--447",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "2",

}

TY - JOUR

T1 - Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

AU - Rubio, Miguel A.

AU - Cabranes, Jose A.

AU - Schally, Andrew V.

AU - Charro, Aniceto L.

PY - 1989/8

Y1 - 1989/8

N2 - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

AB - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

UR - http://www.scopus.com/inward/record.url?scp=0024344908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024344908&partnerID=8YFLogxK

U2 - 10.1210/jcem-69-2-444

DO - 10.1210/jcem-69-2-444

M3 - Article

C2 - 2526819

AN - SCOPUS:0024344908

VL - 69

SP - 444

EP - 447

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -